GeneQiming Completes Over RMB 1 Billion in New Financing to Advance iNKT Cell Therapy Pipeline

Jan 26, 2026 15:01 CST Updated 15:01

Gene Key

Developer of Immune Cell Product Technologies and Provider of Clinical Application Services

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements. This article only introduces drugs related to medical health, not treatment plan recommendations (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

Recently, Beijing Gene Key Life Technology Co., Ltd. (hereinafter referred to as "Gene Key") completed a new round of investment led by Renhe Capital, with a financing amount exceeding1Million yuan. The financing funds will be mainly used for the companyiNKTClinical trials of cell therapy products and the development of new product pipelines, etc.

Founder of Gene Key Life Technology, Mr. Feng JikaiExpressed gratitude to Renhe Capital for its recognition of Gene Key Life Technology, stating that this round of financing marks another significant milestone in the company’s development. Gene Key Life Technology will accelerate product research and development, further solidify its leading position in the iNKT cell therapy field, and strive to achieve commercialization as soon as possible.

According to media reports,Mr. Feng JikaiPreviously engaged in traditional industries, he was the first patient to trial iNKT cell therapy for liver cancer. In 2015, he founded Beijing Gene Key Life Technology Co., Ltd, committing to systematize and industrialize this immunotherapy-based anti-cancer technology.

Product Pipeline:

GKL-006 (Autologous iNKT Cell Injection): Core product, the world's first iNKT cell therapy product targeting liver cancer;

GKL-006RTU (Allogeneic Ready-to-Use iNKT Cell Injection): Recently approved for the treatment of Acute Respiratory Distress Syndrome;

iNKT Cells, or Invariant Natural Killer T Cells (iNKT cells), are a unique type of immune cell. They possess both the specific cytotoxic ability of T cells and the rapid response characteristics of NK cells, without relying on the traditional HLA molecule recognition mechanism. This feature enables them to effectively avoid the risk of graft-versus-host disease (GvHD) while overcoming the immunosuppressive barrier in the solid tumor microenvironment, demonstrating significant application potential in the field of cancer immunotherapy.

References:

Public Information

Scan to join the group

Mastering CAR-T Therapy, Stem Cell Therapy, GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs